- Poster presentation
- Open Access
High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone
© Goto et al; licensee BioMed Central Ltd. 2015
- Published: 28 April 2015
- Coronary Artery
- Significant Positive Correlation
Combination treatment with intravenous immunoglobulin (IVIG) plus prednisolone, newly designed for children with severe Kawasaki disease (KD), significantly reduces coronary artery abnormalities . Prednisolone is administered for approximately 20 days in this regimen.
Our aim was to examine whether adrenal function of the treated patients is suppressed by glucocorticoid administration in this regimen.
This was a prospective study at one medical institution.
We analyzed data from 21 children with KD who were treated with IVIG plus prednisolone between February and June, 2012.
The main outcome measures were cortisol and ACTH values in the morning after the cessation of prednisolone administration and peak cortisol and ACTH values at CRH stimulation tests repeated 0, 2, and 6 months after the treatment.
Morning cortisol and ACTH values after the cessation of prednisolone treatment were suppressed. Peak cortisol values at the first CRH stimulation test ranged from 5.1 to 25.4 mcg/dL and were less than 20 mcg/dL in 17 of 21 patients, but were restored to more than 14.6 mcg/dL in all of them by 6 months after the prednisolone treatment. A significant positive correlation was observed between cortisol values at 09:00 after the prednisolone treatment and peak cortisol values at the following CRH stimulation test (r = 0.770, p < 0.0001).
Adrenal suppression can occur in a high proportion of children with KD treated with IVIG plus prednisolone, despite rather short duration and low administered dose of glucocorticoids.
- Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al: Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012, 379: 1613-20. 10.1016/S0140-6736(11)61930-2.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.